Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In th...Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was administered intragastrically daily before stress. Behavioral results conifrmed that depressive symptoms lessened after treatment with high-dose （150 mg/kg） Shuganjieyu capsule. Immunohistochemistry results showed that high-dose Shuganjieyu capsule signiifcantly increased phosphorylation levels of phosphorylation cyclic adenosine monophosphate response element binding protein and brain-derived neurotrophic factor expression in the medial prefrontal cortex and hippocampal CA3 area. Overall, our results suggest that in rats, Shuganjieyu capsule effec-tively reverses depressive-like behaviors by increasing expression levels of neurotrophic factors in the brain.展开更多
基金supported by the National Natural Science Foundation of China,No.81071093,81171268
文摘Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Ad-ministration of China since 2008. In the clinic, Shuganjieyu capsule is often used to treat mild to moderate depression. In the rat model of depression established in this study, Shuganjieyu capsule was administered intragastrically daily before stress. Behavioral results conifrmed that depressive symptoms lessened after treatment with high-dose （150 mg/kg） Shuganjieyu capsule. Immunohistochemistry results showed that high-dose Shuganjieyu capsule signiifcantly increased phosphorylation levels of phosphorylation cyclic adenosine monophosphate response element binding protein and brain-derived neurotrophic factor expression in the medial prefrontal cortex and hippocampal CA3 area. Overall, our results suggest that in rats, Shuganjieyu capsule effec-tively reverses depressive-like behaviors by increasing expression levels of neurotrophic factors in the brain.
文摘目的观察舒肝解郁胶囊治疗寻常型银屑病的临床疗效及安全性。方法将60例进展期寻常型银屑病患者随机分成对照组30例和试验组30例,另取健康志愿者30例作为健康对照组。对照组予以口服复方甘草酸苷片每次50 mg tid,外用卤米松/三氯生乳膏和卡泊三醇软膏涂擦于患处,bid。试验组在对照组治疗的基础上,予以口服舒肝解郁胶囊每次0.72 g tid。2组患者1个疗程均为4周,共治疗4个疗程。比较2组患者的临床疗效和药物不良反应的发生情况。并比较3组患者的汉密尔顿抑郁量表(HAMD)评分、汉密尔顿焦虑量表(HAMA)评分、血清中去甲肾上腺素(NE)、多巴胺(DA)及5-羟色胺(5-HT)的含量。结果治疗后,试验组和对照组的总有效率分别为96.67%(29/30例)和66.67%(20/30例),差异有统计学意义(P<0.01)。治疗前,试验组、对照组和健康对照组的HAMD评分分别为(21.55±5.62),(20.93±5.57),(8.18±1.98)分;HAMA评分分别为(17.69±4.78),(18.04±4.14),(7.44±2.12)分;NE分别为(6.95±2.31),(6.78±2.26),(2.09±1.11)μg·g^(-1);DA分别为(8.02±2.22),(8.16±2.31),(4.68±1.34)μg·g^(-1);5-HT分别为(62.67±21.18),(61.88±21.55),(21.15±8.66)μg·g^(-1),试验组、对照组的上述指标与健康对照组比较差异均有统计学意义(P<0.01)。治疗后,试验组和对照组的HAMD评分分别为(13.46±3.65),(18.89±3.86)分;HAMA评分分别为(10.75±2.83),(16.64±3.59)分;NE分别为(3.25±2.16),(4.78±1.32)μg·g^(-1);DA分别为(4.65±1.42),(6.88±2.19)μg·g^(-1);5-HT分别为(32.34±10.95),(46.65±20.26)μg·g^(-1),差异均有统计学意义(P<0.01)。试验组和对照组治疗期间未发生药物不良反应。结论舒肝解郁胶囊治疗寻常型银屑病的临床疗效显著,能有效改善患者的精神状态,调节外周血单胺类神经递质水平,且安全性较高。
